These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33030641)

  • 61. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
    Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
    Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
    Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.
    West AH; Blazer KR; Stoll J; Jones M; Weipert CM; Nielsen SM; Kupfer SS; Weitzel JN; Olopade OI
    Fam Cancer; 2018 Oct; 17(4):495-505. PubMed ID: 29445900
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T
    Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.
    Leedom TP; LaDuca H; McFarland R; Li S; Dolinsky JS; Chao EC
    Cancer Genet; 2016 Sep; 209(9):403-407. PubMed ID: 27751358
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Multigene Panel Sequencing Identifies a Novel Germline Mutation Profile in Male Breast Cancer Patients.
    Al Saati A; Vande Perre P; Plenecassagnes J; Gilhodes J; Monselet N; Cabarrou B; Lignon N; Filleron T; Telly D; Perello-Lestrade E; Feillel V; Staub A; Martinez M; Chipoulet E; Collet G; Thomas F; Gladieff L; Toulas C
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762649
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Novel Nonsense Variants c.58C>T (p.Q20X) and c.256G>T (p.E85X) in the CHEK2 Gene Identified dentified in Breast Cancer Patients from Balochistan.
    Baloch AH; Khosa AN; Bangulzai N; Shuja J; Naseeb HK; Jan M; Marghazani IB; Kakar MU; Baloch DM; Cheema AM; Ahmad J
    Asian Pac J Cancer Prev; 2016; 17(3):1089-92. PubMed ID: 27039729
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Irrelevance of CHEK2 variants to diagnosis of breast/ovarian cancer predisposition in Polish cohort.
    Myszka A; Karpinski P; Slezak R; Czemarmazowicz H; Stembalska A; Gil J; Laczmanska I; Bednarczyk D; Szmida E; Sasiadek MM
    J Appl Genet; 2011 May; 52(2):185-91. PubMed ID: 21120647
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Association of two mutations in the CHEK2 gene with breast cancer.
    Bogdanova N; Enssen-Dubrowinskaja N; Feshchenko S; Lazjuk GI; Rogov YI; Dammann O; Bremer M; Karstens JH; Sohn C; Dörk T
    Int J Cancer; 2005 Aug; 116(2):263-6. PubMed ID: 15810020
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical applicability of the Polygenic Risk Score for breast cancer risk prediction in familial cases.
    Lakeman IMM; Rodríguez-Girondo MDM; Lee A; Celosse N; Braspenning ME; van Engelen K; van de Beek I; van der Hout AH; Gómez García EB; Mensenkamp AR; Ausems MGEM; Hooning MJ; Adank MA; Hollestelle A; Schmidt MK; van Asperen CJ; Devilee P
    J Med Genet; 2023 Apr; 60(4):327-336. PubMed ID: 36137616
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results.
    Pritzlaff M; Summerour P; McFarland R; Li S; Reineke P; Dolinsky JS; Goldgar DE; Shimelis H; Couch FJ; Chao EC; LaDuca H
    Breast Cancer Res Treat; 2017 Feb; 161(3):575-586. PubMed ID: 28008555
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers.
    Kriege M; Jager A; Hollestelle A; Berns EM; Blom J; Meijer-van Gelder ME; Sieuwerts AM; van den Ouweland A; Collée JM; Kroep JR; Martens JW; Hooning MJ; Seynaeve C
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1879-87. PubMed ID: 25958056
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy.
    Kriege M; Hollestelle A; Jager A; Huijts PE; Berns EM; Sieuwerts AM; Meijer-van Gelder ME; Collée JM; Devilee P; Hooning MJ; Martens JW; Seynaeve C
    Br J Cancer; 2014 Aug; 111(5):1004-13. PubMed ID: 24918820
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Haplotypes of the I157T CHEK2 germline mutation in ethnically diverse populations.
    Kaufman B; Laitman Y; Gronwald J; Winqvist R; Irmejs A; Lubinski J; Pylkäs K; Gardovskis J; Miklasevics E; Friedman E
    Fam Cancer; 2009; 8(4):473-8. PubMed ID: 19609724
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Clinical utility of testing for PALB2 and CHEK2 c.1100delC in breast and ovarian cancer.
    Woodward ER; van Veen EM; Forde C; Harkness EF; Byers HJ; Ellingford JM; Burghel GJ; Schlech H; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ; Gareth Evans D
    Genet Med; 2021 Oct; 23(10):1969-1976. PubMed ID: 34113003
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CHEK2 mutations and the risk of papillary thyroid cancer.
    Siołek M; Cybulski C; Gąsior-Perczak D; Kowalik A; Kozak-Klonowska B; Kowalska A; Chłopek M; Kluźniak W; Wokołorczyk D; Pałyga I; Walczyk A; Lizis-Kolus K; Sun P; Lubiński J; Narod SA; Góźdż S
    Int J Cancer; 2015 Aug; 137(3):548-52. PubMed ID: 25583358
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study.
    Johnson N; Fletcher O; Naceur-Lombardelli C; dos Santos Silva I; Ashworth A; Peto J
    Lancet; 2005 Oct 29-Nov 4; 366(9496):1554-7. PubMed ID: 16257342
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer.
    Yadav S; LaDuca H; Polley EC; Hu C; Niguidula N; Shimelis H; Lilyquist J; Na J; Lee KY; Gutierrez S; Yussuf A; Hart SN; Davis BT; Chao EC; Pesaran T; Goldgar DE; Dolinsky JS; Couch FJ
    J Natl Cancer Inst; 2021 Oct; 113(10):1429-1433. PubMed ID: 33146377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.